SB202190 (FHPI)

For research use only. Not for use in humans.

目录号：S1077

CAS No. 152121-30-7

SB202190 (FHPI)是一种有效的p38 MAPK抑制剂，靶向作用于p38α/β，无细胞试验中IC50为50 nM/100 nM，有时用于代替SB 203580研究其在体内对SAPK2a/p38的潜在作用。SB202190 可通过诱导自噬和血红素氧化酶1来抑制内皮细胞的凋亡。SB202190可显著抑制Erastin依赖的铁死亡ferroptosis。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1091.41	现货
25mg	RMB 1189.49	现货
100mg	RMB 3017.14	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的SB202190 (FHPI)发表文献122篇：

Immunity, 2021, S1074-7613(21)00210-7

PubMed: 34115964 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):316

PubMed: 33767160 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13046

PubMed: 34165921 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(14)7420

PubMed: 34299039 ( click the link to review the publication )

Front Oncol, 2021, 11:657210

PubMed: 34026633 ( click the link to review the publication )

J Nutr Biochem, 2021, S0955-2863(21)00262-X

PubMed: 34407450 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4463

PubMed: 33923316 ( click the link to review the publication )

Food Chem Toxicol, 2021, 157:112550

PubMed: 34517076 ( click the link to review the publication )

Biosci Rep, 2021, 41(3)BSR20192668

PubMed: 33616153 ( click the link to review the publication )

Cell Regen, 2021, 10(1):32

PubMed: 34599392 ( click the link to review the publication )

J Mol Med (Berl), 2021, 10.1007/s00109-021-02047-5

PubMed: 33611659 ( click the link to review the publication )

Integr Biol (Camb), 2021, 13(6):139-152

PubMed: 33989405 ( click the link to review the publication )

Oncotarget, 2021, 12(9):878-890

PubMed: 33953842 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )
J Neuroinflammation, 2020, 17(1):364

PubMed: 33261639 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Theranostics, 2019, 9(17):5065-5084

PubMed: 31410202 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )
Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19409

PubMed: 31857650 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Microb Pathog, 2019, 130:204-212

PubMed: 30885749 ( click the link to review the publication )

J Physiol Biochem, 2019, 75(4):475-487

PubMed: 31399951 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

J Virol, 2018, 92(4)e01463-17

PubMed: 29167338 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5074

PubMed: 29568077 ( click the link to review the publication )
Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)E2114

PubMed: 28991210 ( click the link to review the publication )

Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):7442

PubMed: 28785085 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

J Dent Res, 2016, 95(7):769-75

PubMed: 26961489 ( click the link to review the publication )

Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Sci Rep, 2016, 6:30904

PubMed: 27485764 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )
J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )
PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

产品描述

特性

SB 202190 与SB 203580极为相似。

靶点

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

体外研究

SB 202190显著抑制内源本底和和抗Fas抗体诱导的MAPKAPK 2活性，且抑制效果呈剂量依赖性。SB 202190本身就足以诱导Jurkat细胞和Hela细胞的死亡：通过激活CPP 32样半胱氨酸蛋白酶，可阻断Bcl - 2的表达。p38β可减轻而p38α可加剧由SB 202190诱导的细胞凋亡^[2]。在HaCaT细胞中SB 202190强烈抑制由紫外线诱导的cox - 2蛋白表达和 mRNA水平^[3]。用SB 202190处理肾小管上皮细胞（正常大鼠k肝脏-52E），可将由白蛋白引发的炎症（单核细胞趋化蛋白-1，MCP - 1）或肿瘤生长因子β-1（TGFβ-1）引发的原纤维化（原骨胶原I a1，procollagen-i alpha1）相关基因降低50%^[4]。SB 202190处理A549细胞，可诱导JNK磷酸化（该磷酸化效应呈时间和剂量依赖性）、转录因子ATF - 2磷酸化，并增加AP – 1与DNA的结合^[6]。SB 202190处理促进THP-1和MV4-11细胞的生长。SB 202190可提高c-Raf 和ERK（细胞外信号调节激酶）磷酸化，暗示由SB 202190诱导的白血病细胞增殖过程有Ras-Raf-MEK-mitogen激活的MAPK通路的参与^[7]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	MXTGeY5kfGmxbjDBd5NigQ>?	M{HtNFI2KM7:TR?=	M4LmfVMxKG2rbh?=	NWPHTJczTE2VT9Mg	M3Xw[IF1fGWwdXH0[ZMhfGinIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbjDv[kBpSkRvMjDpckBz\XOyb37zbZZmKHSxIFTB	NH7UO3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKyN\|I2OSd-Mk[yNlMzPTF:L3G+
MDA-MB-231	MUDGeY5kfGmxbjDBd5NigQ>?	NXHNW3FQOiEQvF2=	NILjfGozPCCq		MUDs[ZN{\W6nczDDR2wzKGmwZIXjeIlwdiCkeTDUUmbPuQ>?	MknPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMEC4OFgoRjJ4MUCwPFQ5RC:jPh?=
rBMSCs	MVnGeY5kfGmxbjDBd5NigQ>?	MUOxNEDPxE1?	Mn3FNk42KGh?		Mnnj[IVxemW\|c3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiRWLLJIFv\CCyM{i=	Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUOyOlYoRjJ4MEWzNlY3RC:jPh?=
MG63	MXrGeY5kfGmxbjDBd5NigQ>?	NWPDOIx2OTBxMkCvN\|Ah\|ryP	NWjpRlBsOjRiaB?=		NGH6SWt{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhdGW4ZXygc4YheGixc4Doc5J6dGG2ZXSgdFM5KGmwZIXj[YQh[nliQ3TDcFIhcW5iYTDjc45k\W62cnH0bY9vKC2mZYDlcoRmdnRibXHucoVz	Mni1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7OUizNVIoRjJ3OUm4N\|EzRC:jPh?=
MG63	NXnBRVgxSXCxcITvd4l{KEG\|c3H5	MXSxNE8zOC9\|MDFOwG0>	MXKyOEBp		M3L3ZZNq\26rZnnjZY51dHliZHXjdoVie2WmIITo[UBieG:ydH;zbZMhemG2ZTDv[kBOTzZ\|IHnu[JVk\WRiYomgR4REdDJ?	M3nVcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUm4N\|EzLz5{NUm5PFMyOjxxYU6=
HTSMCs	MVrGeY5kfGmxbjDBd5NigQ>?	M1jaOlAvOS9zL{GwJO69VQ>?	MXqxJIg>		MXHpcohq[mm2ZXSgR29TVS1{LXnu[JVk\WRiSF:tNUBxem:2ZXnuJIxmfmWuczDhcoQhdVKQQTDlfJBz\XO\|aX;u	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl{MUS2OEc,OjV7MkG0OlQ9N2F-
MIA PaCa-2	NGHtdWxHfW6ldHnvckBCe3OjeR?=	NX7qOYxJOjEEoN88US=>	NXfBXIM6OjRiaB?=		NHHXXnFz\WS3Y3XkJIxi[3SjdHWgZYNkfW23bHH0bY9vKGmwIHPvcYJqdmG2aX;uJJdqfGhiYn;0bEAzNUSJIHHu[EBFNWGubH;z[eKh	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
MIA PaCa-2	M2nhWWZ2dmO2aX;uJGF{e2G7	M1z3W\|IxyqEQvF2=	M{CxN\|I1KGh?		NWnkeVJZemW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	NVjSfFBDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
BxPC-3	M2WwPWZ2dmO2aX;uJGF{e2G7	NX;1N3d6OjEEoN88US=>	NVXQV2U{OjRiaB?=		NFrGbZpz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=>	NWHNTGNGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
AsPC-1	M2D4W2Z2dmO2aX;uJGF{e2G7	NFrhcoozOMLizszN	MVmyOEBp		MWXy[ZN2dHS\|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?=	NH7WTWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
MIA PaCa-2	MknYSpVv[3Srb36gRZN{[Xl?	NUDyelY2OjEEoN88US=>	MYOyOEBp		NHHnZWFmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJJdp\W5iY3;tZolv\WRid3n0bEBodHWlb4PlJIFv[WyxZ4O=	MmLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
MIA PaCa-2	M4jMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2ru[\|IxyqEQvF2=	MWqyJIg>		NHjSbVR{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh6OES4PUc,OjV6OEi0PFk9N2F-
BxPC-3	MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLKNlDDqM7:TR?=	MWSyJIg>		MlTEd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	Mn7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
AsPC-1	NFmwc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFH1[FMzOMLizszN	NGLlOG4zKGh?		NVS2XWRze2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	NIr2fJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
HEY	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnntNlDDqM7:TR?=	M{mxNVIhcA>?		M3\we5NmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NWLXU3hRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
OVCAR-3	NYLoOXRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfxSmUzOMLizszN	MYKyJIg>		NF;0Xph{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	NWXLfnlyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
SK-OV-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPZNlDDqM7:TR?=	NGPE[owzKGh?		M{HaR5NmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NXjNSI9NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
MH7A	NWDRc5c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoLUNlQhcA>?		NY\aWYgzemWrbn\vdoNmeyC2aHWgbY5pcWKrdH;yfUBm\m[nY4TzJI9nKFiDTh?=	MoO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NkK5OlYoRjJ3OE[yPVY3RC:jPh?=
MH7A	MoTyRZBweHSxc3nzJGF{e2G7	Ml;oNlUh\|ryP	NVHRcHN3OjRiaB?=		MUHy[ZZmenOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpcoR2[2WmIHL5JHhCViCjbnSgZ4F2e2WmIHHwc5B1d3OrczDv[kBk\WyuczD2bYEh[WO2aY\heIlwdiCxZjDKUms>	Ml\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NkK5OlYoRjJ3OE[yPVY3RC:jPh?=
SCC25	NFLuWnlHfW6ldHnvckBCe3OjeR?=	Ml3BNlAh\|ryP	M1\PbFI1KGh?		M4HEO4lv[3KnYYPld{BifXSxcHjh[5khdGW4ZXy=	M4nEWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0OFAxLz5{NUizOFQxODxxYU6=
HaCaT	M{LaW2Z2dmO2aX;uJGF{e2G7	NVvLfJFXPSEEtV2=	NU\mb3pwOjRiaB?=		NG\RRmtqdmirYnn0d{BKTk5vzsOtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NEO1N{c,OjV6M{SzOVM9N2F-
HaCaT	NES4fIZHfW6ldHnvckBCe3OjeR?=	NXvnOpFJPSEEtV2=	NH3pVIgzPCCq		MUHpcohq[mm2czDJSm4u\|rFvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	M1r3WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO0N\|U{Lz5{NUizOFM2OzxxYU6=
HPAEpiCs	M{HHVGZ2dmO2aX;uJGF{e2G7	MWmxM\|MwOTBizszN	M3vaVlEhcA>?		NFLkZ2Zz\WS3Y3XzJHMyWC2rbnT1Z4VlKEmFQV2tNUBxem:2ZXnuJIFv\CCvUl7BJIV5eHKnc4Ppc44h[W6mIIDyc41wfGW{IHHjeIl3cXS7	NFnKT3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUezOFkxOCd-MkW3N\|Q6ODB:L3G+
HPAEpiCs	Mki3SpVv[3Srb36gRZN{[Xl?	NVfjbYNDOS9\|L{GwJO69VQ>?	NUL5[VZJOSCq		MmTMbY5pcWKrdIOgV\|FRNXO2aX31cIF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbjCgxsA>	NXrweZN5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N\|Q6ODBpPkK1O\|M1QTByPD;hQi=>
HPAEpiCs	NX[y[lN2TnWwY4Tpc44hSXO\|YYm=	NEPqfpUyNzNxMUCg{txO	M2HJXVEhcA>?		NH7i[JZqdmirYnn0d{BUOVBidHnt[U1l\XCnbnTlcpRtgSC\|dHnteYxifGWmIHOtTpVvKHCqb4PwbI9zgWyjdHnvci=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd\|NEmwNEc,OjV5M{S5NFA9N2F-
K562	NFzxSoRHfW6ldHnvckBCe3OjeR?=	MXKxNOKh\|ryP	NI[wc4YyyqCq	M17W[GROW09?	Mlu1bY5pcWKrdIOgdZVqdmGlcnnu[U1qdmS3Y3XkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6NEC0N{c,OjV4OESwOFM9N2F-
PANC-1	M{L0ZmZ2dmO2aX;uJGF{e2G7	NXj3RoNrOTBizszN	NVfWRnYyOSCq		M3fSfIVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|MkKyNkc,OjV4M{KyNlI9N2F-
BxPC-3	MXzGeY5kfGmxbjDBd5NigQ>?	MorHNVAh\|ryP	NEfjd2cyKGh?		Moex[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB?	NFfieWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zNlIzOid-MkW2N\|IzOjJ:L3G+
K562	NIixfVFHfW6ldHnvckBCe3OjeR?=	MVOwMlI2NTFizszN	NW\QXYF3OjRiaB?=		NHjiWGJ{fXCycnXzd4V{KHKnc4\ldoF1em:uLXnu[JVk\WRiSELBXEBxcG:\|cHjvdplt[XSrb36=	MmrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MUmzPVIoRjJ3NkG5N\|kzRC:jPh?=
THP-1	NGrhXVZHfW6ldHnvckBCe3OjeR?=	M3rzVVUhyrWP	MmXlNkBp		MWPzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNic3XjdoV1cW:wIH;mJGlNNTIQsTDpcoR2[2WmIHL5JFI4V0iFaH;sJJBtfXNiRmPMMVHDqA>?	M2DmflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm4OlYyLz5{NUW5PFY3OTxxYU6=
WB	Mlu2SpVv[3Srb36gRZN{[Xl?	M{H4SVIx6oDLzszNxsA>	MXGzNQKBkW2rbh?=		M4GzcYRm[3KnYYPld{B1cGViTGDTMUBweiCOVFGtbY5lfWOnZDDJUE03KGGwZDDUUmYu\|rIEoIDyc4R2[3Srb36=	NWTzdm15RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|A3QDJpPkK1OVMxPjh{PD;hQi=>
RAW 264.7	NVm5VpF7TnWwY4Tpc44hSXO\|YYm=	M{nQelExyqEQvF2=	MUizNQKBkW2rbh?=		NYnlV4VCcW6mdXPld{BkcGG{YXP0[ZJqe3SrYzD2ZYN2d2yjdHnvckBw\iCRQ4RCpC=>	NWHCbnRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlE{QTlpPkK1OFYyOzl7PD;hQi=>
RAW 264.7	NYfFWG41TnWwY4Tpc44hSXO\|YYm=	MmnqNVDDqM7:TR?=	NYnFdoZSOzEkgJntbY4>		NXjFe4hn[XS2ZX71ZZRmeyC2aHWg[YZn\WO2czDv[kBQWEdib36gc5N1\W:lbHHzeEBz\XS{YXP0bY9v	NIrsOHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS2NVM6QSd-MkW0OlE{QTl:L3G+
HaCaT	NYHCeplwTnWwY4Tpc44hSXO\|YYm=	NYLTU4hmPDEEoN88US=>	MmDVN{0zPCCq	MlK4SG1UVw>?	MoT6doVlfWOnczD0bIUh[WOldX31cIF1cW:wIH;mJHpQNTF?	NXfyTI9sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N\|U1QDVpPkK1OFM2PDh3PD;hQi=>
H9c2	NGDTSopHfW6ldHnvckBCe3OjeR?=	MWm1NOKh\|ryPwrC=	M2nKV\|EzKGh?		M13FbpJm\HWlZYOgUGRJKHKnbHXhd4Uh[W6mIF3NVEBtd3O\|	NHi5WJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0OVgyQCd-MkWyOFU5OTh:L3G+
HSCs	NHfmS2tCeG:ydH;zbZMhSXO\|YYm=	M3HnOVI2KM7:TR?=	M17IUlI1yqCq		MVTzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN?	M{TQVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OU[xPVUxLz5{NEm2NVk2ODxxYU6=
THP-1	Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWe3NkBp	NWnKXW16TE2VTx?=	M3LtSmlEPTB;ND63{txO	M{jneVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG1NFg4Lz5{NEixOVA5PzxxYU6=
MDDCs	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{DI[\|czKGh?	NYT0VnV5TE2VTx?=	NV3vTnNsUUN3MEKuO:69VQ>?	NYnpSJpLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
MDDCs	MkGzSpVv[3Srb36gRZN{[Xl?	NHrVWnAxNTF3IN88US=>	NEjQXFQ1QCCq	M{LzTGROW09?	M{LQS5N2eHC{ZYPz[ZMhUU[QLd8xJIFv\CCLUD2xNEBxem:mdXP0bY9vyqB?	NU\YelR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
MDDCs	MlHYSpVv[3Srb36gRZN{[Xl?	MWWwMVE2KM7:TR?=	NVPZeVlqPDhiaB?=	NY\pPFc1TE2VTx?=	MlnabY5pcWKrdIOgUWlRNTGjLDDNTXAuOWJiYX7kJHJCVlSHUzDwdo9lfWO2aX;u	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzNUC4O{c,OjR6MUWwPFc9N2F-
MDDCs	M{K2NWZ2dmO2aX;uJGF{e2G7	NGDoOIcyOCEQvF2=	NW\Qdo1YOy53IHi=	NILo[2VFVVOR	MUjicI9kc3NiRVLPWkBIWCxiYoX0JI5wfCCYU2[gS{Bu\WSrYYTl[EBmdnS{eTDpcpRwKGi3bXHuJG1FTEO\|	Mn7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUWwPFcoRjJ2OEG1NFg4RC:jPh?=
macrophages	MUXGeY5kfGmxbjDBd5NigQ>?	MU[x5qCK\|ryP	MW[0MlXjiImq		M{nSR4NwdXCuZYTlcJkhcW6qaXLpeJMhVVRvSVnJMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCQRj5OvmI>	MlXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MEi2N\|MoRjJ2OEC4OlM{RC:jPh?=
PDL	M3foUGZ2dmO2aX;uJGF{e2G7	NY\tdZhoOjEEoN88UeKh	M3LWT\|MxKG2rbh?=	MmL2SG1UVw>?	Mkj1d4lodmmoaXPhcpRtgSCrbnjpZol1eyC2aHWgeIVve2muZTDmc5Jk\S2vZXTpZZRm\CCETWCtNkBmgHC{ZYPzbY9v	MoHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NkGwPFEoRjJ2NU[xNFgyRC:jPh?=
AGS	MlHISpVv[3Srb36gRZN{[Xl?	Ml3KOUDPxE1?	NGfyOY4{OCCvaX6=		NYLPUZVje3WycILld5Nme8LiMT3pcoR2[2WmIHPhd5Bie2VvODDhcoQh[2G\|cHHz[U0{KGGldHn2ZZRqd25?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV2N{i3PEc,OjR3NEe4O\|g9N2F-
H520	MorFSpVv[3Srb36gRZN{[Xl?	NUPteYtqOTEEoNM1US=>	NXPzU5RjOSCq	MYjEUXNQ	MWjk[YNz\WG\|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy\|	NGPyU4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
H1703	NX7VW\|VVTnWwY4Tpc44hSXO\|YYm=	NH;1PVcyOMLiwsXN	MmPYNUBp	MX3EUXNQ	MYfk[YNz\WG\|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy\|	NGXSSVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
H520	NHvCe4ZHfW6ldHnvckBCe3OjeR?=	MlT1NVDDqML3TR?=	MojJNVIhcA>?	M4rnTmROW09?	NULiSYhvcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5	NIrNcJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
H1703	NX7CW49tTnWwY4Tpc44hSXO\|YYm=	M130N\|ExyqEEtV2=	M3f3VFEzKGh?	NEnhXoJFVVOR	M1;rVYlvcGmkaYTzJJBmdWW2cnX4[YQu\WyrY3n0[YQhVVOKMjDwdo91\WmwIIP0ZYJqdGm2eR?=	MoT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3M{C0O\|UoRjJ2NUOwOFc2RC:jPh?=
H520	NUP5S4hDTnWwY4Tpc44hSXO\|YYm=	NYTIfm9nOTEEoNM1US=>	MYC2JIg>	MVjEUXNQ	NGC0dpZ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhdGW4ZXzzJI9nKHWkaYH1bZRqdi2lb37qeYdifGWmIF3TTFIhcW5icHXt[ZRz\XinZD30doVifGWmwrDj[YxtKGyrbnW=	NYH2OI5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|A1PzVpPkK0OVMxPDd3PD;hQi=>
H1703	NEC1S5RHfW6ldHnvckBCe3OjeR?=	NGrTUJYyOMLiwsXN	NYHnNYU3PiCq	MUjEUXNQ	Mlzrd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n	M162S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwOFc2Lz5{NEWzNFQ4PTxxYU6=
MC3T3-E1	NEPhU2ZHfW6ldHnvckBCe3OjeR?=	M1XqVlAvOy9\|L{OwJO69VQ>?	MoXiNUBp		NW\yRW1E[XS2ZX71ZZRmeyCWTl[t{tEucW6mdXPl[EBOVVBvOTDlfJBz\XO\|aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>	MlzrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEK2PVYoRjJ2NUCyOlk3RC:jPh?=
MC3T3-E1	MnfnSpVv[3Srb36gRZN{[Xl?	M3\yWVMxKM7:TR?=	MVOxJIg>		MlX3ZZR1\W63YYTld{BVVkZvzsGtd5RqdXWuYYTl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVyMk[5Okc,OjR3MEK2PVY9N2F-
HUVECs	MWLGeY5kfGmxbjDBd5NigQ>?	M3ztU\|ExyqEEtV2=	NEXZWmwyKGh?		NF7TeJZqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDDXGNNOSCycn;keYN1cW:w	M172eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi3PVY1Lz5{NES4O\|k3PDxxYU6=
AGS	Ml\NSpVv[3Srb36gRZN{[Xl?	Mn\BNVDDqML3TR?=	M4e4UlMxyqCvaX6=		MV7pcohq[mm2czDJUE0y\|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
MKN-45	M3jVbGZ2dmO2aX;uJGF{e2G7	MXexNOKhyrWP	M4HuRVMxyqCvaX6=		M1;U[IlvcGmkaYTzJGlNNTIQsj3pcoR2[2WmIHHjeIl3[XSrb36gc4YheDN6	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
AGS	M37CZmZ2dmO2aX;uJGF{e2G7	NF\aR5cyOMLiwsXN	NHTwdW4{OMLibXnu		NHrBPIxifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>?	NXrSc3RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|k3QDFpPkK0OFc6PjhzPD;hQi=>
MKN-45	NX3HRndDTnWwY4Tpc44hSXO\|YYm=	NITkVIwyOMLiwsXN	NHXw[Wk{OMLibXnu		M131dIF1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v	NV7hOYFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|k3QDFpPkK0OFc6PjhzPD;hQi=>
AGS	M4Xt[WZ2dmO2aX;uJGF{e2G7	MUOxNOKhyrWP	M3e3b\|MxyqCvaX6=		NHzLblN{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y\|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?=	MlrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
MKN-45	MV7GeY5kfGmxbjDBd5NigQ>?	NWLCVW12OTEEoNM1US=>	M4TFNlMxyqCvaX6=		NFriXld{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y\|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?=	M{\6UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEe5OlgyLz5{NES3PVY5OTxxYU6=
DCs	M2C1O2Z2dmO2aX;uJGF{e2G7	NUjs[XpFOjEEoN88US=>	MmDJNeKhcA>?		NYi1NIlF\GWlcnXhd4V{KEmOLUGyJJBzd2S3Y4Tpc44>	MnK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{S2N\|YoRjJ2NEO0OlM3RC:jPh?=
HUVEC	MXnGeY5kfGmxbjDBd5NigQ>?	MX[yNEDPxG4EoB?=	NEXzbI42KGh?	MkHHSG1UVw>?	M3[3bZJm\HWlZYOgZ5l1d2urbnWg[ZhxemW\|c3nvckBt\X[nbIOgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK=	NF\uWZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4PVA3Oid-MkSxPFkxPjJ:L3G+
A 549	MoW4SpVv[3Srb36gRZN{[Xl?	Mo\BOVAh\|ryP	MXuxJIg>		NHTYWZdl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIFnMMVjDqA>?	M2PTNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe5Olg5Lz5{NEG3PVY5QDxxYU6=
H520	MoHBSpVv[3Srb36gRZN{[Xl?	NU[1c5N1PS9zMDFOwG0>	MWSxJIg>	NVrOV\|ZUTE2VTx?=	M4LjVoRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs	M3mxPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO4PVA{Lz5{NEGzPFkxOzxxYU6=
H1703	M3K4RmZ2dmO2aX;uJGF{e2G7	MmnqOU8yOCEQvF2=	NHrVZ28yKGh?	NV\ZXpZnTE2VTx?=	NW\T[VE5\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw>	NYr0eVNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|g6ODNpPkK0NVM5QTB\|PD;hQi=>
H520	NWjt[GdpTnWwY4Tpc44hSXO\|YYm=	NGLJcZoyOMLiwsXN	M{fwTVEzKGh?	NHTRVVRFVVOR	M4C2UoRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|OEmwN{c,OjRzM{i5NFM9N2F-
H1703	MkHFSpVv[3Srb36gRZN{[Xl?	MWWxNOKhyrWP	MlmzNVIhcA>?	NVXDd5pvTE2VTx?=	M3WwSoRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	M1q2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUO4PVA{Lz5{NEGzPFkxOzxxYU6=
MCF-7	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUixNOKh\|ryP	MlPaNlTDqGh?		NWPxW2F6cW6qaXLpeJMhfGinIFPSNVA5NWmwZIXj[YQh[2WubDDk[YF1cA>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{OEi1N{c,OjRzMki4OVM9N2F-
HPAEpiCs	NEHGUnpHfW6ldHnvckBCe3OjeR?=	NXnTVVlROC5zL{GvNVAh\|ryP	MomyNUBp		NF7SenZqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDjVGxCOsLicILveIVqdiCjbnSgcXJPSSCneIDy[ZN{cW:w	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4OUG1PEc,OjRyNkmxOVg9N2F-
podocytes	MX\GeY5kfGmxbjDBd5NigQ>?	NXjiN2NsOTEEoN88US=>	MkPINUBp		NVvmbGZMcW6qaXLpeJMhXEeIzsKxMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{jNRXBMKGGwZDDFdosyNzMEoB?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB\|NkKxNkc,OjRyM{[yNVI9N2F-
MCF-7	MonmSpVv[3Srb36gRZN{[Xl?	MWGxNOKh\|ryP	MnrDNUBp	Mn:zSG1UVw>?	M4nGWpJm\HWlZYOgeIhmKFeDLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQheDN6IF3BVGs>	M2XONVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG5NFkxLz5{NECxPVA6ODxxYU6=
MCF-7	M{G2PGZ2dmO2aX;uJGF{e2G7	M1m1elExyqEQvF2=	M2nkclI1KGh?	MWnEUXNQ	NYXYRppucW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzOUC5NEc,OjRyMUmwPVA9N2F-
HAPI	M1\0VWZ2dmO2aX;uJGF{e2G7	NHz5[5AyOC9{MD:0NOKh\|ryP	NYWxSZk6OSCq		MXzpcohq[mm2czDUR2RFNWmwZIXj[YQheDN6L1rOT{BOSVCNIIDoc5NxcG:{eXzheIlwdg>?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4OUGyNEc,OjN7NkmxNlA9N2F-
HAPI	M4TXOWZ2dmO2aX;uJGF{e2G7	MVeyNOKh\|ryPwrC=	M4nYW\|EhcA>?	NXzHXG5ZTE2VTx?=	MofrZZR1\W63YYTld{BVS0SGLXnu[JVk\WRiYXP0bZZifGmxbjDv[kBqVk:VIHHu[EBxem:mdXP0bY9v	NGrjNnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2PVEzOCd-MkO5OlkyOjB:L3G+
HepG2	NFLxUm1HfW6ldHnvckBCe3OjeR?=	NEK2Zlg{PTBibl2=	Mn;vNlQhcA>?		NUPWNWQ{cW6qaXLpeJMhfGinIHTl[5VmdGmwLXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOziPQWDL	NFfIPZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mzN\|E6QCd-MkO5N\|MyQTh:L3G+
AGS	NF:xSlFHfW6ldHnvckBCe3OjeR?=	M4\uUlExyqEQvF2=	NILmRnc{OCCvaX6=		MUHpcohq[mm2czDjZZNx[XOnLUOgZYN1cX[jdHnvckBidmRiaX7obYJqfGmxbjDv[kBGWkt?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MEm5OEc,OjN6NUC5PVQ9N2F-
HepG2	M1G1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUf0V5VkOC13MDFOwG0>	NFy5eVM1QCCq		Mlf5bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhyN{WwPEc,OjN6MEe1NFg9N2F-
BEL7404	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MViwMVUxKM7:TR?=	NVzMRVh{PDhiaB?=		NV7MOnl6cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NYDzdoE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NFc2ODhpPkKzPFA4PTB6PD;hQi=>
HL7702	MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSwMVUxKM7:TR?=	MXe0PEBp		MW\pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NG\JZYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{iwO\|UxQCd-MkO4NFc2ODh:L3G+
HepG2	NHn3d41HfW6ldHnvckBCe3OjeR?=	NGfR[IkxNTVyIN88US=>	M3rX[FI1KGh?		MVvpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKHB\|ODDkc5dve3S{ZXHtJJBzd3SnaX7zJG1CWEuDUFuyMEBCXEZ{LDDNV2syKGGwZDDIV3AzPyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M{TtdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEC3OVA5Lz5{M{iwO\|UxQDxxYU6=
BEAS-2B	M3m3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\Dd5BEOTBizszN	Mn7sN\|AhdWmw		M3HPT5JmfmW{c3XzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IFjDTS=>	NG\Q[nI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4OFA{PCd-MkO3PFQxOzR:L3G+
BEAS-2B	MYLDfZRwfG:6aYT5JGF{e2G7	MXixNEDPxE1?	M3i5elMxKG2rbh?=		MVfpcohq[mm2ZXSgeIhmKGmwY4LlZZNmKGmwIFzETEBidmRiSVytPEBmgHC{ZYPzbY9v	MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OESwN\|QoRjJ\|N{i0NFM1RC:jPh?=
BEAS-2B	MlzLSpVv[3Srb36gRZN{[Xl?	MVGxNEDPxE1?	NHeyN44{OCCvaX6=		NHHDc\|Fl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjZZNx[XOnLUOsJGJi\CCjbnSg[oF{	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd6NECzOEc,OjN5OESwN\|Q9N2F-
H9c2	MmS4SpVv[3Srb36gRZN{[Xl?	NYXtZXE5OC5yMT:wMlEwOSEQvF2=	NUC5eY9HOSCq		MW\heJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25uIH3SUmEhdGW4ZXzzMEBidmRicILvcY91\XJiYXP0bZZqfHl?	Mn75QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5N{SyOVIoRjJ\|N{e0NlUzRC:jPh?=
H9c2	M{PyR2Z2dmO2aX;uJGF{e2G7	MknENUDPxE1?	MYixJIg>		MVvy[YR2[2W\|IGTOSk3PuSCmaYLlZ5RtgSC\|dHnteYxifGWmIICzPEBOSVCNIIDoc5NxcG:{eXzheIlwdg>?	NUPBcHZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3O\|QzPTJpPkKzO\|c1OjV{PD;hQi=>
U937	NIjvSIJHfW6ldHnvckBCe3OjeR?=	NVj5dmtXOTEEoN88UeKh	M{n0e\|EhcA>?		NWX4OppP[WK{b3fheIV{KHSqZTDjZYZn\WmwZTDl[oZm[3Rib36gUWtRNTFiYX7kJHBROkGlzsGgcXJPSSC2cnHud4NzcXC2aX;uZYwhdGW4ZXzz	NFfCWYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewO\|M5Pyd-MkO3NFc{QDd:L3G+
U937	MYLGeY5kfGmxbjDBd5NigQ>?	NHP3d2cyOMLizszNxsA>	NVXDfWhxOSCq		NUH2VG1b[WK{b3fheIV{KGOjZn\lbY5mNWmwZIXj[YQhVUuSLUGg[I94di2{ZXf1cIF1cW:wIHHu[EBRWDKDY98xJJVxNXKnZ4XsZZRqd25?	NUPYSoJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFc{QDdpPkKzO\|A4Ozh5PD;hQi=>
U937	Mn24SpVv[3Srb36gRZN{[Xl?	M3zzfVExyqEQvF5CpC=>	NH\Q[4wyKGh?		Mlzhd5VxeHKnc4Pld{BkNUq3bjDhcoQhS1KHQjDwbI9{eGixconsZZRqd25iaX6gZ4Fn\mWrbnWteJJm[XSnZDDj[Yxte8Li	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyN{O4O{c,OjN5MEezPFc9N2F-
A549	MYDGeY5kfGmxbjDBd5NigQ>?	MU[wMlMwOy9\|MDFOwG0>	NEjreVEyKGh?		MYPzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiQWTQ{tNUNW2nZHnheIVlKEORWD2yJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW\|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHoEoB?=	NEfBU\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NFY4PCd-MkO2PFA3PzR:L3G+
A549	MVrGeY5kfGmxbjDBd5NigQ>?	M3\FdFExyqEQvF5CpC=>	M2D3[VAuOzBibXnu		M1TRRolvcGmkaYTzJGFVWM7\|UzDpcoR2[2WmIIC0Nk9xPDRiTVHQT{BidmRicEO4JG1CWEticHjvd5Bpd3K7bHH0bY9v	NFvzVHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NFY4PCd-MkO2PFA3PzR:L3G+
A549	NH3Re4NHfW6ldHnvckBCe3OjeR?=	MUixNOKh\|ryPwrC=	MV2xJIg>		NEK0N2FqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm=	NXTPW4NWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA3PzRpPkKzOlgxPjd2PD;hQi=>
A549	M1z1b2Z2dmO2aX;uJGF{e2G7	NIrIO3YyOMLizszNxsA>	MYOxJIg>		Mni5doVlfWOnczDBWHDPu1Nvc4TpcZVt[XSnZDDjVGxCOiCyaH;zdIhwenmuYYTpc47DqA>?	M13GblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkiwOlc1Lz5{M{[4NFY4PDxxYU6=
A549	NGHXc4VHfW6ldHnvckBCe3OjeR?=	MVqxNOKh\|ryPwrC=	NEjDN2UyKGh?		NYqwWIpFemWmdXPld{BCXFEQs2Ot[Y5p[W6lZXSg[Y57gW2jdHnjJIFkfGm4aYT5JI9nKGOSTFGyxsA>	Mn;WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEC2O\|QoRjJ\|NkiwOlc1RC:jPh?=
PC12	M2HROGZ2dmO2aX;uJGF{e2G7	NUfYcFRkOTBxMkCvOFAh\|ryP	M2DWZVHDqGh?		M13hPIlvcGmkaYTzJGpPUyCjbnSgdFM5	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV6NEO1O{c,OjN3OESzOVc9N2F-
HK-2	M3PqVmFxd3C2b4Ppd{BCe3OjeR?=	Mn75NlDDqM7:TR?=	NHuwSIkzPCCq		M2jQbIlvcGmkaYTzJGVTUyCjbnSgdFM5VUGSSx?=	M3fmUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUSzNVUyLz5{M{W0N\|E2OTxxYU6=
H9c2	MoThSpVv[3Srb36gRZN{[Xl?	NV:2c4lIOcLizszN	MXOxJIg>		NYfK[ZY4emWmdXPld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCvUl7BJIxmfmWuczDhcoQheHKxbX;0[ZIh[WO2aY\peJk>	M4G3fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{WzOlk6Lz5{M{O1N\|Y6QTxxYU6=
H9c2	M1HCe2Z2dmO2aX;uJGF{e2G7	MlrxNeKh\|ryP	NWWwfGV4OSCq		MnHWdoVlfWOnczDUUmYu\|rFvZX7oZY5k\WRiQWCtNUBxem:vb4TldkBi[3Srdnn0fS=>	NYLrRoVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVM3QTlpPkKzN\|U{Pjl7PD;hQi=>
H1650	NVvjUJc4TnWwY4Tpc44hSXO\|YYm=	NVzDNVd1OTEEoN88UeKh	NWPWOXJMOSCq	M4T6WmROW09?	NHLzfZll\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:\|ZXVCpINmdGy\|	NYfQVIplRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1703	MYjGeY5kfGmxbjDBd5NigQ>?	M4HBblExyqEQvF5CpC=>	M3r5bFEhcA>?	MWLEUXNQ	Mnjr[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR\|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>?	NX7PflY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyNlg3QTZpPkKzNlI5Pjl4PD;hQi=>
H1650	NWXRSJpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq5fm1KOTEEoN88UeKh	MlK3NUBp	NGHSTmZFVVOR	MmXL[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	NGTPdmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KyPFY6Pid-MkOyNlg3QTZ:L3G+
H1703	M2fKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV:xNOKh\|ryPwrC=	M{TNV\|EhcA>?	M4nOZWROW09?	Mmrk[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	M1vjdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkK4Olk3Lz5{M{KyPFY6PjxxYU6=
medulloblastoma cells	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKG2nZIXscI9jdGG\|dH;tZUBk\WyuczDoZZJjd3KrbnegbIV1\XKxeonnc5V{KHC2Y3ixJIdmdmViYomgUXRVKGG\|c3H5MEBGSzVyIE2gN{4xODZizszNMi=>	M1;iRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG3OlMyLz5zN{SxO\|Y{OTxxYU6=
neural precursor cells	NYXUelF1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				NYqxcoVCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDu[ZVz[WxicILlZ5Vze2:{IHPlcIx{KGK7IF3UWEBie3OjeTygSWM2OCB;IEiuNFY{KM7:TT6=	NInYd489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxO\|Y{OSd-MUe0NVc3OzF:L3G+
RAW264.7	NVPkPGhWSW62aXnu[oxidW2jdH;yfUBie3OjeR?=		Mke5NVAhdWmwcx?=		NY[zO5VKSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJG5QKHC{b3T1Z5Rqd25iaX7jeYJifGWmIH\vdkAyOCCvaX7zJJBzcW:{IITvJGxRWy2laHHscIVv\2VibXXhd5Vz\WRiYX\0[ZIhOThiaILzJIJ6KEe{aXXzd{Bu\XSqb3SsJGlEPTBiPTCxOkDPxE1w	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh\|MUe5PEc,OjJ6M{G3PVg9N2F-
BL21(DE3)	MYHGeY5kfGmxbjDhd5NigQ>?		NFexfI03OCCvaX7z		M{DTSmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDIbZM3NXSjZ3fl[EBDWkR2IHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFqRFWzLUBk\WyuczD1d4lv\yCkaX;0bY56dGG2ZXSgbIl{fG:wZTDIOEBx\XC2aXTlJIF{KHO3YoP0doF1\SCjZoTldkA3OCCvaX7zJIJ6KEGucHjhV4Nz\WWwIHHzd4F6NCCLQ{WwJF0hOy52IN88UU4>	NIH5N4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG5OVczOyd-MkixPVU4OjN:L3G+
RAW264.7	MoXhSpVv[3Srb36gZZN{[Xl?				MXjQdo91\WO2aX;uJIFo[Wmwc4SgRoFkcWyudYOgZY51cHKjY3nzJJBzd3SnY4TpeoUh[W62aXflckBidmRibHX0bIFtKHSxeHnuMYRqeGi2aHXybYEhfG:6aX6gZ4hqdWW{aXOgdJJwfGWrbjDt[YRq[XSnZDDjfZRwfG:6aXPpeJkhcW5ibX;1d4UhWkGZMk[0Mlch[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdIm=	MnXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2OEW1NFQoRjF5NEi1OVA1RC:jPh?=
A673	NWDyWoFbeUiWUzDhd5NigQ>?				NEG1fYJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	Mnr0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NUfRZoNxeUiWUzDhd5NigQ>?				MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	NVrkdmpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	NGiwc4VyUFSVIHHzd4F6				NIjUbGhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MmLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MYrxTHRUKGG\|c3H5				NHXLV\|lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	NGfIXnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	M2rWU5FJXFNiYYPzZZk>				M{XFU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{	M161b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	M4jvZZFJXFNiYYPzZZk>				M{PUNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGxCVi13IHPlcIx{	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MoTUdWhVWyCjc4PhfS=>				M1vrcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	M4LwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NG\tNHRyUFSVIHHzd4F6				Ml3jdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>?	MofqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NH3rfo1yUFSVIHHzd4F6				NGjFOHZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	MknTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	M4fzXpFJXFNiYYPzZZk>				NH3jRYRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	M4K0bJFJXFNiYYPzZZk>				M{\3WJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	NGjkW2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MXnxTHRUKGG\|c3H5				MnvadWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM>	Mmj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	MYDxTHRUKGG\|c3H5				MoDrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=>	Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NYfoW2w3eUiWUzDhd5NigQ>?				MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDPTHMuPTBiY3XscJM>	M17VeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NUHhXoFWeUiWUzDhd5NigQ>?				NGjYVGdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	MoXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	NV6zOZNNeUiWUzDhd5NigQ>?				MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NYrMVGdzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	M2nSfJFJXFNiYYPzZZk>				NVXoXlU3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MkTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MYjxTHRUKGG\|c3H5				Mnj4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	NV;QO\|NqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	NWDk[mpMeUiWUzDhd5NigQ>?				MlLTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>?	MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	MUjxTHRUKGG\|c3H5				NXTufHpweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	M171RpFJXFNiYYPzZZk>				Mk[xdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	NVe4NoJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

体内研究

SB 202190通过抑制p38减弱了由人脊髓灰质炎IgG（PV-IgG）在被动转移小鼠模型中诱发的水泡形成^[5]。在脓毒症内毒素模型中，与对照组相比，经SB 202190处理可显著提高存活率^[8]。

激酶实验： ^[1]	- 合并体外酶活检测: p38α 和 p38β 溶解在25mM的Tris - HCl缓冲液中，PH 7.5，含0.1mM EGTA，髓鞘碱性蛋白（0.33毫克/毫升）作为底物。人工操作条件用50μL [γ-³³P]ATP于30 °C孵育10分钟；Biomek 2000自动化工作站用25μL [γ-³³P]ATP在96孔板室温孵育40分钟。ATP和乙酸镁浓度分别为0.1mM和10mM。所有检测都用MgATP起始。人工检测将孵育液滴到磷酸纤维素纸上，浸泡在50mM磷酸中。用5μL磷酸终止反应，后将孵育液点滴在P30过滤垫上。滤膜在50mM磷酸中漂洗四次以去除ATP，在用丙酮（人工孵育）或甲醇（工作站孵育）处理后，干燥并用放射性计量。
细胞实验： ^[2]	- 合并 Cell lines: Jurkat, 和 HeLa细胞 Concentrations: 溶解于DMSO, 终浓度~50 μM Incubation Time: 24 小时 Method: 细胞血清饥饿后，用不同浓度SB 202190处理24小时。用台盼蓝或PI染色后经流式细胞仪分析，以检测细胞活力。凋亡细胞核用H33258染色。 (Only for Reference)
动物实验： ^[5]	- 合并 Animal Models: C57BL/6J 小鼠皮内注射无菌的对照IgG或人脊髓灰质炎IgG做对比。 Dosages: 12.5 μg Administration: 皮内注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%H2O	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download SB202190 (FHPI) SDF

分子量	331.34
化学式	C₂₀H₁₄N₃OF
CAS号	152121-30-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

选择性强的p38 MAPK抑制剂

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
活性最高的p38 MAPK抑制剂

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
用于临床的p38 MAPK抑制剂

VX-702 : Phase II for Rheumatoid Arthritis.
最新的p38 MAPK抑制剂

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

研究领域

产品类型

定制您的化合物库

SB202190 (FHPI)

客户使用Selleck生产的SB202190 (FHPI)发表文献122篇：

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download SB202190 (FHPI) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

相关p38 MAPK产品